Table 1.
Baseline characteristic of patients in the two groups.
| Category | < 65 years (n = 198) |
65 ≤ years (n = 45) |
P-value |
|---|---|---|---|
| pT stage, n (%) | |||
| pT2b | 80 (40.4) | 9 (20.0) | 0.032 |
| pT3a | 21 (10.6) | 3 (6.7) | |
| pT3b | 36 (18.2) | 12 (26.7) | |
| pT3c | 61 (30.8) | 21 (46.7) | |
| pN stage, n (%) | |||
| pN0 | 82 (41.4) | 16 (35.6) | 0.011 |
| pNX | 72 (36.4) | 36 (57.8) | |
| pN1 | 44 (22.2) | 3 (6.7) | |
| Histology, n (%) | |||
| Serous | 96 (48.5) | 32 (71.1) | 0.044 |
| Clear-cell | 64 (32.3) | 9 (20.0) | |
| Mucinous | 6 (3.0) | 0 (0.0) | |
| Endometrioid | 32 (16.2) | 4 (8.9) | |
| Hysterectomy, n (%) | 186 (93.9) | 42 (93.3) | 0.549 |
| CA-125, IU/mL | 1114.2 (2102.3) | 1520.7 (2530.0) | *0.261 |
| Positive ascites cytology, n (%) | 100 (50.5) | 29 (64.4) | 0.091 |
| Chemotherapy, n (%) | 198 (100.0) | 45 (100.0) | n.a |
Data are presented as mean (standard deviation) or proportion (%).
Student’s t-test, chi-square test, or Fisher's exact test was used as appropriate.
SD, standard deviation; CA, cancer antigen.
*Logarithmically transformed when analyzed.